Nuvation Bio Inc.
Tremor tracks 8 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
Trials
- NUVBNuvation Bio Inc.10Calm
A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene
Running, no new patientsPhase 2173 patientsMain results: Jun 7, 2024 - NUVBNuvation Bio Inc.10Calm
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
Running, no new patientsPhase 2217 patientsMain results: Jun 11, 2025 - NUVBNuvation Bio Inc.0Calm
Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
Signing up patientsPhase 240 patientsMain results: Sep 2030 - NUVBNuvation Bio Inc.0Calm
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Signing up patientsPhase 3365 patientsMain results: Dec 1, 2028 - NUVBNuvation Bio Inc.0Calm
Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma
Not started yetPhase 3140 patientsMain results: May 2029 - NUVBNuvation Bio Inc.0Calm
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Signing up patientsPhase 3180 patientsMain results: Aug 30, 2030 - NUVBNuvation Bio Inc.0Calm
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
Signing up patientsPhase 3194 patientsMain results: Jan 2029 - NUVBNuvation Bio Inc.0Calm
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
Running, no new patientsPhase 1/2466 patientsMain results: Mar 2027
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
4 sales (0 not pre-planned) · 1 purchase
- Hattersley GaryCHIEF SCIENTIFIC OFFICER · Aug 19, 2026Sold 100,000 sharesabout $709 thousand · pre-planned
- Markel StacyCHIEF PEOPLE OFFICER · Jun 23, 2026Sold 125,000 sharesabout $753 thousand · pre-planned
- Wentworth KerryCHIEF REGULATORY OFFICER · Jun 23, 2026Sold 63,000 sharesabout $379 thousand · pre-planned
- Sauvage PhilippeChief Financial Officer · Jun 23, 2026Sold 47,668 sharesabout $286 thousand · pre-planned
- Mashal RobertBoard member · Jun 9, 2026Bought 25,000 sharesabout $118 thousand ·
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.